贝伐珠单抗与雷珠单抗治疗湿性年龄相关性黄斑变性的使用情况:CATT结果的影响及阿柏西普的引入
该回顾性分析评估了CATT结果发表及阿柏西普上市对贝伐珠单抗和雷珠单抗玻璃体腔注射使用的影响,纳入164,188名Medicare受益人和881,381名商业保险受益人。结果显示,CATT发表后许多偏好雷珠单抗的眼科医生转向贝伐珠单抗,而偏好贝伐珠单抗者大多继续使用;阿柏西普的引入对这两种药物的偏好影响很小。
要点
- CATT发表后,69.7%的雷珠单抗主导医生减少了雷珠单抗使用,74.6%的贝伐珠单抗主导医生维持贝伐珠单抗主导使用。
- 阿柏西普上市后,53.1%的雷珠单抗主导医生减少雷珠单抗使用,41.9%的贝伐珠单抗主导医生减少贝伐珠单抗使用。
- 商业保险受益人分析结果与Medicare受益人相似。
核心结论
- CATT结果发表后,许多偏好雷珠单抗的眼科医生转向贝伐珠单抗,而多数偏好贝伐珠单抗者继续偏好贝伐珠单抗。
- 阿柏西普的引入对雷珠单抗或贝伐珠单抗的偏好影响很小。
研究设计与样本
- 回顾性治疗模式分析,纳入2008年1月1日至2014年12月31日期间接受至少1次抗血管内皮生长因子注射的164,188名Medicare受益人和881,381名商业保险受益人。
主要发现
- 在CATT发表前主要使用雷珠单抗的317名眼科医生中,221名(69.7%)在CATT发表后减少雷珠单抗使用,96名(30.3%)继续≥80%的时间使用雷珠单抗。
- 在CATT发表前主要使用贝伐珠单抗的1041名眼科医生中,777名(74.6%)继续贝伐珠单抗主导使用,264名(25.4%)在CATT发表后减少贝伐珠单抗使用。
- 在阿柏西普上市前主要使用雷珠单抗的145名眼科医生中,77名(53.1%)减少雷珠单抗使用,68名(46.9%)在阿柏西普上市后继续≥80%的时间使用雷珠单抗。
- 在阿柏西普上市前主要使用贝伐珠单抗的909名眼科医生中,381名(41.9%)减少贝伐珠单抗使用,528名(58.1%)继续贝伐珠单抗主导使用。
- 商业保险受益人中观察到相似结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether publication of Comparison of Age-related macular degeneration Treatment Trial (CATT) results and introduction of aflibercept to the marketplace affected intravitreal bevacizumab and ranibizumab utilization. DESIGN: Retrospective analysis of treatment patterns. METHODS: We calculated weekly bevacizumab and ranibizumab utilization during 3 timeframes: (1) before CATT publication, (2) between CATT publication (April 28, 2011) and assignment of a unique aflibercept billing code (January 1, 2013), and (3) afterward for 164,188 Medicare beneficiaries with neovascular macular degeneration receiving ≥1 anti-vascular endothelial growth factor injection(s) from January 1, 2008 to December 31, 2014. We identified ophthalmologists who predominantly (≥80%) administered bevacizumab or ranibizumab and evaluated changes in preferences over the 3 periods. We replicated analyses on 881,381 commercially insured beneficiaries. RESULTS: Among 317 ophthalmologists administering predominantly ranibizumab to Medicare beneficiaries pre-CATT, 221 (69.7%) reduced ranibizumab use post-CATT, whereas 96 (30.3%) continued using ranibizumab ≥80% of the time. Findings were reversed among 1041 ophthalmologists who predominantly administered bevacizumab pre-CATT-777 (74.6%) continued bevacizumab-predominant use while 264 (25.4%) reduced bevacizumab use post-CATT. Among the 145 ophthalmologists who predominantly administered ranibizumab before aflibercept's availability, 77 (53.1%) reduced ranibizumab utilization and 68 (46.9%) continued using ranibizumab ≥80% of the time after aflibercept became available. Corresponding numbers among the 909 ophthalmologists who predominantly administered bevacizumab pre-aflibercept were 381 (41.9%) reducing and 528 (58.1%) continuing bevacizumab-predominant use. Similar results were observed for commercially insured patients. CONCLUSIONS: Many ophthalmologists who favored ranibizumab switched to bevacizumab after CATT publication, while most who favored bevacizumab before CATT publication continued favoring it afterward. Aflibercept's introduction had little impact on preferences for ranibizumab or bevacizumab.
引用
- Pershing S, Talwar N, Armenti ST, et al. Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept. Am J Ophthalmol. 2019. PMID: 31100217. doi:10.1016/j.ajo.2019.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。